TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer-Reference-Cited by-同舟云学术

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Published:2018-09-12 Issue:6 Volume:25 Page:1766-1773
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

De Laere Bram,Oeyen Steffi,Mayrhofer Markus,Whitington Tom,van Dam Pieter-Jan^ORCID,Van Oyen Peter,Ghysel Christophe,Ampe Jozef,Ost Piet^ORCID,Demey Wim,Hoekx Lucien,Schrijvers Dirk,Brouwers Barbara,Lybaert Willem,Everaert Els G.^ORCID,De Maeseneer Daan,Strijbos Michiel,Bols Alain,Fransis Karen,Beije Nick^ORCID,de Kruijff Inge E.,van Dam Valerie^ORCID,Brouwer Anja,Goossens Dirk^ORCID,Heyrman Lien,Van den Eynden Gert G.,Rutten Annemie,Del Favero Jurgen^ORCID,Rantalainen Mattias,Rajan Prabhakar^ORCID,Sleijfer Stefan,Ullén Anders,Yachnin Jeffrey,Grönberg Henrik^ORCID,Van Laere Steven J.,Lindberg Johan,Dirix Luc Y.

Funder

Belgian Foundation Against Cancer

Flemish cancer society

Royal College of Surgeons/Cancer Research UK

Erling-Persson Family Foundation

Swedish Research Council

Swedish Cancer Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

2. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

3. Machine learning based androgen receptor regulatory gene-related random forest survival model for precise treatment decision in prostate cancer;Heliyon;2024-09

4. Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: A systematic review and meta-analysis;Clinical Genitourinary Cancer;2024-09

5. Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial;European Urology Oncology;2024-09